Recruiting NA INTERVENTIONAL 1-arm NCT05853198

Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability (CASPER)

Sponsor: Azienda Ospedaliera Universitaria Integrata Verona

Conditions PDAC - Pancreatic Ductal Adenocarcinoma

Updated 3 times since 2023 Last updated: May 8, 2023 Started: Dec 29, 2022 Primary completion: May 31, 2026 Completion: May 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates PDAC - Pancreatic Ductal Adenocarcinoma and is currently actively recruiting participants. Azienda Ospedaliera Universitaria Integrata Verona leads this study, which shows 3 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Recruiting NA
Jun 2023 — Jul 2024 [monthly]

Recruiting NA

First recorded

Dec 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Azienda Ospedaliera Universitaria Integrata Verona

Data source: Azienda Ospedaliera Universitaria Integrata Verona

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Verona, Italy